Amrubicin
- Generic Name
- Amrubicin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25NO9
- CAS Number
- 110267-81-7
- Unique Ingredient Identifier
- 93N13LB4Z2
- Background
Amrubicin is a third-generation synthetic anthracycline currently in development for the treatment of small cell lung cancer. Pharmion licensed the rights to Amrubicin in November 2006. In 2002, Amrubicin was approved and launched for sale in Japan based on Phase 2 efficacy data in both SCLC and NSCLC. Since January 2005, Amrubicin has been marketed by Nippo...
- Indication
Investigated for use/treatment in lung cancer .
- Associated Conditions
- -
- Associated Therapies
- -
Amrubicin + Cyclophosphamide in Advanced Solid Organ Malignancies
- First Posted Date
- 2009-04-30
- Last Posted Date
- 2015-12-23
- Lead Sponsor
- Lawrence Einhorn
- Target Recruit Count
- 36
- Registration Number
- NCT00890955
- Locations
- ๐บ๐ธ
Northern Indiana Cancer Research Consortium, South Bend, Indiana, United States
๐บ๐ธSiteman Cancer Center, St. Louis, Missouri, United States
๐บ๐ธProvidence Portland Medical Center, Portland, Oregon, United States
AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy
- First Posted Date
- 2007-10-22
- Last Posted Date
- 2019-11-06
- Lead Sponsor
- Celgene
- Target Recruit Count
- 637
- Registration Number
- NCT00547651
- Locations
- ๐บ๐ธ
Northwest Alabama Cancer Center, Muscle Shoals, Alabama, United States
๐บ๐ธCedars-Sinai Outpatient Cancer Center, Los Angeles, California, United States
๐บ๐ธCancer Care Associates of Fresno Medical Group, Inc., Fresno, California, United States
Study of Amrubicin With or Without Cisplatin Versus Etoposide-cisplatin for Extensive Stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-17
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Celgene
- Target Recruit Count
- 99
- Registration Number
- NCT00388960
- Locations
- ๐ณ๐ฑ
Academisch Medisch Centrum, Amsterdam, Netherlands
๐ณ๐ฑMedisch Spectrum Twente - Dept of Pulmonary Diseases, Enschede, Netherlands
๐ณ๐ฑAcademisch Ziekenhuis Maastricht, Maastricht, Netherlands
Study of Amrubicin With or Without Herceptin in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2008-09-23
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 66
- Registration Number
- NCT00380835
Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy
- First Posted Date
- 2006-09-12
- Last Posted Date
- 2019-10-24
- Lead Sponsor
- Celgene
- Target Recruit Count
- 75
- Registration Number
- NCT00375193
- Locations
- ๐บ๐ธ
Texas Oncology, P.A., Sammons Cancer Center, Dallas, Texas, United States
๐บ๐ธMedical Oncology Associates, Kingston, Pennsylvania, United States
๐บ๐ธSUNY Upstate Medical Center, Syracuse, New York, United States
Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2009-09-30
- Lead Sponsor
- Celgene Corporation
- Target Recruit Count
- 76
- Registration Number
- NCT00319969
- Locations
- ๐บ๐ธ
New York Oncology Hematology, PC, Albany, New York, United States
๐บ๐ธJohns Hopkins Hospital - The Bunting Blaustein Cancer Research Building, Baltimore, Maryland, United States
๐บ๐ธHematology/Oncology Consultants, St. Louis, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.